News
BMEA
1.260
+0.80%
0.010
Cognition Therapeutics Q2 net loss narrows on lower R&D costs
Reuters · 1d ago
Vaxart Q2 revenue falls on lower government contract income
Reuters · 1d ago
Biomea Fusion price target lowered to $7 from $9 at Citizens
TipRanks · 1d ago
Biomea Fusion (BMEA) Gets a Buy from Oppenheimer
TipRanks · 1d ago
PepGen Q2 net loss narrows as expenses fall
Reuters · 1d ago
Amylyx Pharmaceuticals Q2 posts higher than expected loss
Reuters · 1d ago
Analyst Maintains Buy Rating on Biomea Fusion as Metabolic Pipeline Advances and $4 Price Target Remains Unchanged
TipRanks · 1d ago
BioMea Q2 Loss Shrinks; Data From Phase 2 Trials For Icovamenib In Diabetes Expected In '27
NASDAQ · 1d ago
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Benzinga · 2d ago
Biomea Fusion GAAP EPS of -$0.12 beats by $0.10
Seeking Alpha · 2d ago
Biomea Fusion reports Q2 EPS (12c), consensus (23c)
TipRanks · 2d ago
Biomea Fusion Q2 loss narrows, cash runway into Q2 2027
Reuters · 2d ago
Biomea Fusion Q2 net loss narrows to $8.33 million; R&D expenses fall 44.68% to $9.14 million
PUBT · 2d ago
Press Release: Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Dow Jones · 2d ago
Press Release: Biomea Fusion Reports Second -2-
Dow Jones · 2d ago
Weekly Report: what happened at BMEA last week (0727-0731)?
Weekly Report · 4d ago
Weekly Report: what happened at BMEA last week (0720-0724)?
Weekly Report · 07/27 09:09
Weekly Report: what happened at BMEA last week (0713-0717)?
Weekly Report · 07/20 09:09
Weekly Report: what happened at BMEA last week (0706-0710)?
Weekly Report · 07/13 09:09
Weekly Report: what happened at BMEA last week (0629-0703)?
Weekly Report · 07/06 09:09
More
Webull provides a variety of real-time BMEA stock news. You can receive the latest news about Biomea Fusion, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BMEA
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.